Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 7 | 2024 | 157 | 4.270 |
Why?
|
| Radiosurgery | 17 | 2024 | 361 | 3.010 |
Why?
|
| Head and Neck Neoplasms | 5 | 2023 | 133 | 2.410 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 68 | 2.100 |
Why?
|
| Brain Neoplasms | 14 | 2020 | 647 | 1.910 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2023 | 21 | 1.790 |
Why?
|
| Palliative Care | 3 | 2023 | 51 | 1.600 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2023 | 35 | 1.540 |
Why?
|
| Laryngeal Neoplasms | 2 | 2023 | 16 | 1.420 |
Why?
|
| Neoplasms | 4 | 2023 | 761 | 1.100 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 12 | 0.820 |
Why?
|
| Deglutition | 1 | 2023 | 30 | 0.810 |
Why?
|
| Humans | 36 | 2024 | 32798 | 0.810 |
Why?
|
| Mouth Neoplasms | 1 | 2023 | 19 | 0.800 |
Why?
|
| Tonsillar Neoplasms | 1 | 2023 | 5 | 0.790 |
Why?
|
| Retrospective Studies | 16 | 2023 | 3701 | 0.760 |
Why?
|
| Radiation Injuries | 1 | 2022 | 78 | 0.720 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 217 | 0.680 |
Why?
|
| Prospective Studies | 7 | 2023 | 2327 | 0.680 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 754 | 0.640 |
Why?
|
| Quality of Life | 4 | 2024 | 961 | 0.640 |
Why?
|
| Pain | 1 | 2022 | 294 | 0.640 |
Why?
|
| Cranial Irradiation | 6 | 2020 | 93 | 0.640 |
Why?
|
| Treatment Outcome | 12 | 2023 | 3438 | 0.630 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 6 | 0.630 |
Why?
|
| Papillomaviridae | 1 | 2019 | 22 | 0.620 |
Why?
|
| Prognosis | 10 | 2023 | 1544 | 0.610 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 470 | 0.540 |
Why?
|
| Middle Aged | 18 | 2022 | 12125 | 0.440 |
Why?
|
| Female | 21 | 2024 | 20261 | 0.430 |
Why?
|
| Salvage Therapy | 3 | 2020 | 134 | 0.420 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 428 | 0.400 |
Why?
|
| Male | 21 | 2024 | 19641 | 0.390 |
Why?
|
| Radiodermatitis | 2 | 2024 | 6 | 0.380 |
Why?
|
| Lymph Nodes | 2 | 2023 | 114 | 0.380 |
Why?
|
| Aged | 13 | 2021 | 10538 | 0.330 |
Why?
|
| Meningioma | 2 | 2020 | 58 | 0.320 |
Why?
|
| Incidence | 3 | 2021 | 1238 | 0.290 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4032 | 0.270 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 764 | 0.260 |
Why?
|
| Postoperative Complications | 2 | 2023 | 828 | 0.250 |
Why?
|
| Human papillomavirus 16 | 1 | 2023 | 4 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 24 | 0.210 |
Why?
|
| Adult | 7 | 2020 | 9560 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2020 | 486 | 0.200 |
Why?
|
| Glottis | 1 | 2023 | 7 | 0.200 |
Why?
|
| Palatine Tonsil | 1 | 2023 | 8 | 0.200 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 27 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2022 | 80 | 0.190 |
Why?
|
| Mastectomy | 1 | 2022 | 61 | 0.190 |
Why?
|
| Cisplatin | 1 | 2022 | 81 | 0.180 |
Why?
|
| Radiotherapy | 1 | 2022 | 82 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 112 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 24 | 0.170 |
Why?
|
| Terminology as Topic | 1 | 2021 | 64 | 0.170 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 50 | 0.160 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 16 | 0.160 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 8 | 0.160 |
Why?
|
| Burns | 1 | 2021 | 100 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2019 | 12 | 0.160 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 92 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 58 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 18 | 0.150 |
Why?
|
| Patient Selection | 1 | 2021 | 281 | 0.150 |
Why?
|
| Melanoma | 2 | 2017 | 165 | 0.150 |
Why?
|
| Histiocytic Sarcoma | 1 | 2018 | 2 | 0.150 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 17 | 0.140 |
Why?
|
| Smoking | 1 | 2022 | 531 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 476 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 456 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 2284 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 326 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 599 | 0.100 |
Why?
|
| Survival Rate | 3 | 2020 | 894 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 220 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2024 | 565 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 384 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 594 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 563 | 0.060 |
Why?
|
| Keratins | 1 | 2024 | 37 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 63 | 0.040 |
Why?
|
| Prostate | 1 | 2021 | 69 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 23 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 308 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 121 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2020 | 84 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 156 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 315 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 369 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 282 | 0.040 |
Why?
|
| Mediastinum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 99 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 128 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 169 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 245 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 307 | 0.030 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 148 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 459 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 116 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 205 | 0.030 |
Why?
|
| Child | 1 | 2020 | 2478 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2730 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 3638 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 2183 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1844 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3974 | 0.020 |
Why?
|